GlassScriptPhysician profile
Kirsten E Stuber
NPI 1376948620
$78,842.07
in general payments reported to CMS, 2019-2025
65 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,573 · 2022: $12K · 2023: $27K · 2024: $24K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Honoraria: $18K · Food and Beverage: $13K · Travel and Lodging: $6,547 · Long Term Medical Supply Or Device Loan: $1,265 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,262.00 |
| Honoraria | $17,825.00 |
| Food and Beverage | $13,464.42 |
| Travel and Lodging | $6,547.18 |
| Long Term Medical Supply Or Device Loan | $1,264.84 |
| Education | $299.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31,935.60 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Myriad Genetic Laboratories, INC. | $29,653.92 | 2021-2025 | Myrisk, Mychoice Cdx, Precisetumor |
| Astrazeneca Pharmaceuticals LP | $1,978.30 | 2021-2025 | Imfinzi, Imjudo, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,847.29 | 2021-2025 | |
| Beigene, LTD. | $1,040.00 | 2021 | |
| Incyte Corporation | $752.59 | 2021-2025 | Monjuvi, Monjuvi, Jakafi |
| Fresenius Kabi USA, LLC | $700.00 | 2021 | |
| Pfizer INC. | $691.44 | 2021-2025 | |
| Tempus Ai, INC | $653.92 | 2024-2025 | Xt Cdx |
| Regeneron Healthcare Solutions, INC. | $587.37 | 2022-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $571.38 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Takeda Pharmaceuticals U.S.A., INC. | $568.40 | 2021-2025 | Fruzaqla, Ninlaro, Iclusig |
| Lilly USA, LLC | $489.60 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Aveo Pharmaceuticals, INC. | $486.01 | 2022-2025 | Fotivda |
| Beigene USA, INC. | $418.38 | 2021-2025 | Brukinsa |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $415.90 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $379.97 | 2021-2025 | Opdivo |
| Astellas Pharma US INC | $327.56 | 2023-2024 | Veozah, Padcev, Xospata |
| Genmab U.S., INC. | $321.71 | 2022-2025 | Epkinly, Tivdak |
| Emd Serono, INC. | $317.98 | 2022-2024 | Bavencio |
| Genzyme Corporation | $269.33 | 2021-2025 | |
| Gilead Sciences, INC. | $263.23 | 2022-2025 | Trodelvy |
| Daiichi Sankyo INC. | $252.84 | 2022-2025 | Enhertu, Vanflyta, Datroway |
| Syndax Pharmaceuticals, INC. | $243.66 | 2025 | Revuforj |
| Bayer Healthcare Pharmaceuticals INC. | $219.96 | 2021-2025 | |
| Puma Biotechnology, INC. | $215.18 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $206.43 | 2021-2024 | Onivyde, Somatuline Depot |
| Stemline Therapeutics INC. | $200.47 | 2023-2025 | Orserdu, Elzonris |
| Amgen INC. | $198.55 | 2022-2024 | Kyprolis |
| Epizyme, INC. | $198.34 | 2021-2022 | |
| Seagen INC. | $177.14 | 2021-2023 | Tukysa, Adcetris |
| Karyopharm Therapeutics INC. | $163.33 | 2021-2025 | Xpovio |
| Merck Sharp & Dohme LLC | $162.99 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Celgene Corporation | $151.35 | 2022-2025 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $142.55 | 2024 | Monoferric, Cosela |
| Pharmaessentia USA Corporation | $128.99 | 2025 | Besremi |
| Blueprint Medicines Corporation | $128.61 | 2022-2024 | Ayvakit |
| Genentech USA, INC. | $128.25 | 2023-2025 | Polivy, Lunsumio |
| Adaptive Biotechnologies Corporation | $122.72 | 2025 | Clonoseq |
| Taiho Oncology, INC. | $120.00 | 2022-2025 | |
| Array Biopharma INC | $105.57 | 2021-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $93.16 | 2021-2023 | Epkinly, Imbruvica |
| Rigel Pharmaceuticals, INC. | $92.71 | 2021-2023 | Tavalisse, Rezlidhia |
| Eusa Pharma (US) LLC | $82.01 | 2021 | |
| Geron Corporation | $65.99 | 2025 | Rytelo |
| Janssen Scientific Affairs, LLC | $54.79 | 2025 | Tecvayli, Talvey |
| G1 Therapeutics, INC. | $48.64 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $43.33 | 2024-2025 | |
| Mirati Therapeutics, INC. | $38.00 | 2023 | Krazati |
| Tactile Systems Technology INC | $37.83 | 2023 | Entre Plus, Flexitouch Plus |
| Novocure INC. | $36.98 | 2023 | Optune |
| Morphosys, US INC. | $35.35 | 2022-2023 | Monjuvi |
| Boston Scientific Corporation | $33.36 | 2023 | Watchman Access System |
| Sobi, INC | $32.10 | 2024 | |
| Cti Biopharma Corp. | $31.41 | 2022-2023 | Vonjo |
| Jazz Pharmaceuticals INC. | $26.35 | 2023 | |
| Exelixis INC. | $21.92 | 2025 | Cabometyx |
| Immunocore Limited | $21.85 | 2025 | Kimmtrak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.95 | 2021 | |
| Sumitomo Pharma America, INC. | $16.73 | 2023 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $15.96 | 2024 | Ultomiris |
| Springworks Therapeutics, INC. | $15.22 | 2025 | Ogsiveo |
| Iovance Biotherapeutics, INC. | $15.15 | 2025 | Amtagvi |
| Apellis Pharmaceuticals, INC. | $14.33 | 2024 | Empaveli |
| Eisai INC. | $13.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsten Stuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.